Advertisement Wound Management Technologies signs sales agreement with EWA GSI - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Wound Management Technologies signs sales agreement with EWA GSI

Wound Management Technologies, which markets and distributes wound care products, has signed a commission based, sales agreement for its wound care product, CellerateRx, with EWA Government Systems.

The agreement grants to EWA Government Systems (EWA GSI) the right to market both the gel and powder forms of CellerateRx and will be compensated strictly on a commission basis for products sold.

CellerateRx patented collagen fragments (CRX) are a fraction of the size of native collagen molecules found in other products, and provide the benefits of collagen to the body immediately.

Scott Haire, CEO of Wound Management Technologies, said: “We believe that this agreement is a huge step for us, and that EWA GSI’s capabilities in marketing our product represent a strong alliance with a major distributor that facilitates the needs of government entities.”